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Flt3L Dependence Helps Define an Uncharacterized
Subset of Murine Cutaneous Dendritic Cells
Shamim A. Mollah1,6, Joseph S. Dobrin2,3,6, Rachel E. Feder2,3, Sze-Wah Tse4, Ines G. Matos2,3,
Cheolho Cheong4, Ralph M. Steinman2,3,{ and Niroshana Anandasabapathy2,3,5
Skin-derived dendritic cells (DCs) are potent antigen-presenting cells with critical roles in both adaptive
immunity and tolerance to self. Skin DCs carry antigens and constitutively migrate to the skin-draining lymph
nodes (LNs). In mice, Langerin–CD11b  dermal DCs are a low-frequency, heterogeneous, migratory DC subset
that traffics to LNs (Langerin–CD11b  migDCs). Here, we build on the observation that Langerin–CD11b 
migDCs are Fms-like tyrosine kinase 3 ligand (Flt3L) dependent and strongly Flt3L responsive, which may relate
them to classical DCs. Examination of DC capture of FITC from painted skin, DC isolation from skin explant
culture, and from the skin of CCR7 knockout mice, which accumulate migDCs, demonstrate these cells are
cutaneous residents. Langerin–CD11b  Flt3L-responsive DCs are largely CD24( þ ) and CX3CR1low and can be
depleted from Zbtb46-DTR mice, suggesting classical DC lineage. Langerin–CD11b  migDCs present antigen
with equal efficiency to other DC subsets ex vivo, including classical CD8a cDCs and Langerin þ CD103 þ dermal
DCs. Finally, transcriptome analysis suggests a close relationship with other skin DCs, and a lineage relationship
with other classical DCs. This work demonstrates that Langerin– CD11b  dermal DCs, a previously overlooked
cell subset, may be an important contributor to the cutaneous immune environment.
Journal of Investigative Dermatology (2014) 134, 1265–1275; doi:10.1038/jid.2013.515; published online 16 January 2014

INTRODUCTION
As the primary barrier between the body and the outside
world, the skin is a unique immune organ. The importance of
cutaneous immunity is demonstrated in several ways. First,
successful vaccination strategies rely on delivery of vaccine
antigens to the skin, including vaccinia (Liu et al., 2010) and
dermally delivered influenza (Kenney et al., 2004). Second,
innate immune adjuvants that act on the cutaneous immune
network (imiquimod, resiquimod) can lead to the regression of
lentigo maligna and superficial spreading of basal cell
carcinomas (Schon and Schon, 2008). Third, steady-state
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immune surveillance is critical to prevent skin cancers, as
evidenced by the markedly increased incidence of neoplasia
observed in renal transplant recipients maintained on
immunosuppressive agents (Clark, 2010). Despite the
immune-responsive nature of skin cancers and potential for
skin-resident immune cells to mediate adaptive responses to
cancer and infection, therapies have not been generated
to prevent skin cancer formation. Improved understanding
of adaptive immunity in the cutaneous environment is
needed.
Adaptive cutaneous immunity depends on dendritic cells
(DCs) that abundantly populate the skin and skin-draining
lymph nodes (LNs). DCs are low-frequency hematopoietic
cells, specialized at antigen presentation. DCs educate T cells
to respond to tumor and microbial antigens, control the
developing immune response, and maintain long-term
immune memory to tumors and infections. In the noninflamed
state, human skin contains four known phenotypically distinct
subsets of DCs (Haniffa et al., 2012; Teunissen et al., 2012),
whereas murine skin contains five (Henri et al., 2010). These
DCs continuously migrate from skin to the draining LNs and
are collectively termed migratory dendritic cells (migDCs).
Given such phenotypic heterogeneity amongst skin DCs,
increasing efforts are aimed at identifying their functional
and developmental attributes and correlating these with welldescribed DC subsets in other tissues.
Classical DCs are lymphoid and non-lymphoid DCs that
derive from pre-DCs originating from a common bone marrow
precursor (common DC precursor). The term classical is used
www.jidonline.org 1265
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to distinguish these populations from plasmacytoid DCs
(PDCs) (Merad et al., 2013) and monocyte-derived DCs,
which develop in the setting of inflammation. Classical DCs
broadly may be divided into CD11b þ and CD11b 
populations. Classical DCs that are LN- and spleen-resident
and are CD11b  also express CD8a and CD205 (termed
CD8a þ cDC), whereas CD11b þ LN- and spleen-resident
DCs lack expression of CD8a- (termed CD11b þ cDC). In
peripheral tissue such as skin, CD11b  and CD11b þ may
be additionally divided on the basis of other markers such as
CD103 and Langerin.
In draining LNs, cell-surface expression of CD11c and MHCII
is used to separate the three major DC groups: plasmacytoid
DCs, LN-resident classical DCs (cDCs), and migDCs. MigDCs
include some DCs of classical lineage that are CD11b  and
CD11b þ , such as Langerin þ CD103 þ CD11b  DCs and
Langerin–CD11b þ DCs, respectively (Ginhoux et al., 2009).
MigDCs also include Langerhans cells (LCs) of the epidermis,
whose origin is distinct and which are not seeded from preDCs, but derive instead from radio-resistant precursors (Helft
et al., 2010). Although an additional migratory population of
CD11b  cells was previously identified in skin (Langerin–
CD11b  ) (Henri et al., 2010), these cells have been largely
overlooked and incompletely characterized because they exist
in low abundance in other peripheral tissue such as the lung
and mucosa, although they comprise a significant fraction of
DCs from the skin.
Some DCs are functionally specialized at cross-presentation, the major pathway to present viral and tumor antigens.
These DCs have unique properties that make them attractive
cellular targets for vaccination (Poulin et al., 2010). When
mature, they are superior to cross-present exogenous antigens
on MHC I, ingest dead or dying cells, and produce IL-12 in
response to innate and T cell–derived cues (Yamazaki et al.,
2008; Shortman and Heath, 2010). In skin, Langerin þ
CD103 þ DCs cross-present antigens, and CD8a þ CD11b 
DCs, which also express the C-type lectin CD205 (CD8a DC),
cross-present antigens in lymphoid organs. In skin and other
epithelial tissue, CD103 þ DCs cross-present antigens from
cytolytic viruses and epithelial pathogens (Bedoui et al., 2009)
including influenza (Helft et al., 2012), herpes virus (Bedoui
et al., 2009), and erosive candida (Igyarto et al., 2011). Several
lines of evidence suggest that other skin DCs beyond Langerin þ
CD103 þ DCs may have an important role in priming to
vaccines and pathogens. Langerin þ CD103 þ DCs are not
required in dermal vaccine administration (Flacher et al.,
2012). Furthermore, residual antigen presentation capacity to
cutaneous pathogens including erosive candida (Igyarto et al.,
2011) and vaccinia (Seneschal et al., 2013) is observed in the
absence of Langerin þ CD103 þ DCs. These data suggest that
another DC subset may cross-present antigens locally in the
skin and skin-draining LNs.
Flt3L, a DC hematopoietin, and its receptor (Flt3, FLK2)
regulate classical DC homeostasis of both DCs in lymphoid
organs and DCs at, or arriving from, peripheral tissue
(CD103 þ DC in skin and lungs) (Waskow et al., 2008;
Liu et al., 2009). Migratory Langerin þ CD103 þ DCs, CD8a
lymphoid resident cDCs, and human BDCA3 þ cross1266 Journal of Investigative Dermatology (2014), Volume 134

presenting DCs share developmental dependence on Flt3L
(Ginhoux et al., 2009; Haniffa et al., 2012). Flt3L treatment
biases cDC development to cross-presenting DCs (Bozzacco
et al., 2010). Flt3L expansion of DCs has helped identify
very infrequent but functionally important DCs at epithelial
sites such as blood–brain barrier (Anandasabapathy et al.,
2011) and aortic intima (Choi et al., 2011). However, Flt3L
dependence has not been used to characterize infrequent DCs
in the skin or migDCs in the skin-draining LNs.
Here we analyze the cutaneous residence, migratory properties, developmental dependence, transcriptome, and functional properties of a cutaneous Langerin–CD11b  migratory
DC subset (abbreviated Langerin– CD11b  migDC). Our
data suggest that this subset is heterogeneous but contains
highly Flt3L-responsive DCs with potent antigen-presentation
capacity. We demonstrate that Langerin–CD11b  migDCs
share many features with other classical Flt3L-dependent DCs.
RESULTS
Langerin–CD11b  migDCs are Flt3L dependent

We examined the expansion of migDC in the skin-draining
LNs of mice in the presence and absence of in vivo Flt3L
treatment. MigDCs can be gated as CD11cint and IAIE
(MHCII)hi and further divide into Langerin þ known DC
subsets including Langerin þ CD103 þ DCs and Langerin þ
CD103  DCs (which include Langerhans cells). Langerin–
migDC subsets include Langerin–CD11b þ DCs and
Langerin–CD11b  DCs (Henri et al., 2010). (Figure 1a, and
gating in Supplementary Figure S1A online). In C57BL/6 mice
(Figure 1a) and Langerin GFP mice (Figure 1b) treated with
Flt3L, we observed a major expansion of LN migDCs within
the Langerin– compartment, comprising both CD11b þ and
CD11b  cells. This was intriguing because our lab and others
have shown a parallel expansion of CD11b  (CD8a þ ) and
CD11b þ (CD8a-) cDCs in lymphoid tissue after Flt3L treatment (Bozzacco et al., 2010). LN DC subset numbers were
quantified from Flt3L-treated, untreated, and knockout mice
(Figure 1c). Langerin–CD11b þ and Langerin–CD11b  subsets were expanded most significantly by Flt3L treatment. Flt3L
loss affected Langerin þ CD103 þ DCs, and Langerin–
CD11b þ and Langerin–CD11b  subsets.
CD11b  migDCs are skin-resident and traffic to the skindraining LNs

To ascertain whether Langerin–CD11b  cells migrated to the
LNs from skin, or were a contaminant from LN-resident
populations such as CD8a cDCs, we examined skin explants
in which DCs are directly isolated from the skin. CD11b 
cells were present and expanded with Flt3L in ‘‘crawlout’’ DC
isolation from skin (gating, Supplementary Figure S1B online).
We established this in several models: Flt3L doxycyclineinducible mice (Manfra et al., 2003) (Figure 1d), recombinant
Flt3L-treated Langerin GFP mice (Figure 1e, Supplementary
Figure S1B online), recombinant Flt3L-treated C57Bl/6 mice
(Supplementary Figure S1C online), and Flt3L-secreting B16
tumor–treated mice (Supplementary Figure S1D online). In
cDCs, Flt3L creates bias to CD8a CD205 þ cross-presenting
cDCs. Analysis of CD205 þ expression on migDC explants
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Figure 1. Flt3L dependence of migratory dendritic cell (DC) subsets, including Langerin–CD11b  DCs. (a) Schema of lymph node (LN) DCs from Flt3L-tumortreated versus C57Bl/6 (B6) control mice at day 13. PDCs (plasmacytoid DCs), cDCs (classical LN resident DCs), and migDCs (migratory DCs) are labeled.
(b) LN DC subsets Flt3L-treated (upper) versus untreated Langerin–GFP mice. (c) Quantification of migratory DCs from Flt3L-treated, control, Flt3L  /  mice
(quantified per skin-draining LN; error bars show mean ±SD of three individual mice per group, analyzed by an unpaired t-test). (d) Flt3L-induced expansion of
skin-resident DC subsets from ‘‘crawlout’’ skin explants of doxycycline-inducible Flt3L mice given 8 days of doxycycline in their drinking water (top) versus
untreated controls (bottom) (one representative experiment of two). (e) Quantification of DCs isolated from skin explant ‘‘crawlouts’’ of Flt3L-treated versus control
Langerin GFP reporter mice (pooled from the ears of three mice per experiment, one representative experiment of three). (f) aCD205 þ staining of skin DC subsets
from explant cultures of doxycycline-treated (Flt3L þ ) versus untreated (control) mice (pooled from n ¼ 2 mice per condition).

revealed that Langerin–CD11b  DCs contained both
CD205high and CD205low cells in the steady state. However,
a higher percentage of CD11b  cells are CD205high after
treatment with Flt3L (Figure 1f).

Skin migDCs depend on CCR7 for migration to LNs (Forster
et al., 1999). To further validate that Langerin–CD11b  cells
in LNs have migrated from the skin, we examined CCR7  / 
mice treated with Flt3L versus untreated controls. Irrespective
www.jidonline.org 1267
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of Flt3L treatment, LNs from CCR7 knockout mice lack cells
within the CD11cintIAIEhi DC migratory gate (Figure 2a, upper
panel). MigDC subsets including CD11b  cells preferentially
accumulated in skin explants and expanded with Flt3L locally

in the skin (Figure 2a, lower panel). When FITC is applied with
a contact-sensitizing agent to the epidermis of mice, migDCs
rapidly transport FITC from skin to skin-draining LNs. FITC
label was present only in the IAIEhi migratory cells (Figure 2b).
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Figure 2. CD11b  dendritic cells (DCs) are skin-resident and migrate to the skin-draining lymph nodes (LNs). (a) Upper: representative skin-draining LN DCs
gating from CCR7  /  mice treated with Flt3L (left), CCR7  /  untreated controls (middle), and B6 controls (right). Lower: CCR7  /  skin-resident DC subsets
from ‘‘crawlout’’ explants (Flt3L treated versus untreated controls). One of three representative experiments is shown. (b) FITC painting assay with gating on FITC þ
migratory DC versus total migratory DCs in Flt3L-treated (upper) and control mice (lower). CD11b  migDCs (red) directly capture FITC in the skin and traffic to
the skin-draining LNs at 16 hours and 24 hours in C57BL6/WT mice (n ¼ 3 mice per time point). (c) Immunofluorescence of flank sections of Flt3L-treated (upper)
and control (lower) mice co-stained with langerin (green), CD11b (red), and CD11c (magenta) and counterstained with DAPI to visualize cell nuclei. Positions of
Langerhans cells (LCs: Langerin þ , CD11b þ , CD11c þ , #). Dermal DC (CD11c þ ) were further distinguished as Langerin–CD11b  (m), Langerin–CD11b þ
( þ ), and Langerin þ CD11b  (*) were marked in the merged images. Bar ¼ 50 mm for all images.
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were noted after Flt3L treatment, we speculated that the
Langerin–CD11b  subset might be heterogeneous in the
steady state. To address this, we examined CD24 expression,
an additional marker for CD8a cDCs, on migDCs before and
after Flt3L treatment. We observed that Flt3L treatment
expands the percentage of Langerin–CD11b  cells expressing CD24 in the LNs from B40% to B80%, with a more
modest and variable percentage expansion in skin (Figure 3a,
Supplementary Figure S1C-D online). We also noted that in
skin and LNs, an increase in the absolute number of Langerin–
CD11b  CD24 þ cells occurred after Flt3L and a correspondingly higher ratio of Langerin–CD11b  CD24 þ cells in Flt3L
treated versus control mice (quantification, Supplementary
Figure S2 online). An increased percentage of CD24 þ cells
after Flt3L was also observed on CD8a þ cross-presenting
cDCs in LNs. Langerin þ DC subsets have high CD24
expression, and CD11b þ DCs have lower CD24 þ levels
at baseline. In CD11b þ migDCs, CD24 þ percentage was
not markedly altered after Flt3L treatment in LNs and skin
(Figure 3a and Supplementary Figure S1C-D online). These
data suggest that Flt3L expands CD24 þ Langerin–CD11b 
cells. In contrast, during FITC painting in the presence of a

Examination of FITC þ migDCs versus all migDCs demonstrated an enhanced representation of FITC þ Langerin–
CD11b  cells during inflammation and FITC painting. Several
populations of DCs transported FITC to the skin-draining LNs,
yet a greater fraction of Langerin–CD11b  and Langerin–
CD11b þ DC subsets were present that labeled with FITC
when compared with all migDCs after FITC painting
(Figure 2b). These data suggest that Langerin–CD11b  DCs,
similar to other migDCs, can transport FITC from the skin to
the skin-draining LNs. To visualize Langerin–CD11b  DCs
directly in skin, immunofluorescence staining was performed
in Flt3L-treated and untreated mice. LCs were marked in
the epidermis (Langerin þ CD11b þ CD11c þ ). Contained
within dermal CD11c þ cells, we observed Langerin–
CD11b þ , Langerin–CD11b  , and Langerin þ CD11b  DCs
(Figure 2c).
Langerin–CD11b  migDCs are heterogenous but contain a
Flt3L-responsive CD24hi CX3CR1low DC population

Given that CD205high- and CD205low-expressing cells were
present in the steady state within Langerin– CD11b 
migDCs, yet enhanced numbers of CD205high expressing cells
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Figure 3. Flt3L-responsive CD11b  migratory dendritic cells (migDCs) include CD24high CX3CR1low subsets. (a) In skin and skin-draining lymph nodes (LNs), a
subset of CD11b  migDCs are CD24 þ and expand with Flt3L. Gated pre (open) and post (closed) Flt3L in the LN and skin explant (lower) as compared with
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receptor (DTR) mice, which allows specific depletion of cDCs
and their precursors, but does not affect PDCs, monocytes, or
macrophages (Meredith et al., 2012a,b; Satpathy et al., 2012).
At 24 and 48 hours post DT treatment, an overall gross reduction in total number of LN-resident cDCs was observed, as
expected (Figure 4a, gating Supplementary Figure S3A online).
MigDCs were also rapidly depleted (Figure 4b). Langerin–
CD11b  cells were efficiently depleted along with other
cDCs in the LNs (Figure 4b) and in skin (Figure 4c and
Supplementary Figure S3B online) with few residual cells left.
These data suggest that Langerin–CD11b  cells are a Zbtb46expressing classical DC subset that shares the same origin as
cDCs.

proinflammatory contact-sensitizing agent, we observe that
the expanded CD11b  population is predominantly CD24low
(Supplementary Figure S1E online).
To further investigate Langerin–CD11b  heterogeneity, we
examined the expression of CX3CR1 using CX3CR1-GFP
reporter mice (Jung et al., 2000). The chemokine receptor
CX3CR1 (fractaline) is abundantly expressed on CD11b þ LNresident cDCs and largely absent from the majority of CD8a
LN-resident cDCs, which helps distinguish these two subsets
(Figure 3b). The small fraction of CD8a þ DCs that express
CX3CR1 lack cDC capacity for IL-12 secretion, cross-presentation of antigen, and resemble CD8a cDCs (Bar-On et al.,
2010). After Flt3L treatment, CD8a þ CD24hi CX3CR1low cDCs
(red, upper) remain well distinguished from CD11b þ CD24low
CX3CR1hi cDCs (blue, upper) (Figure 3b). In the steady state,
Langerin–CD11b  cells are B50% CD24high CX3CR1low as
compared with Langerin–CD11b þ migDCs, which were predominantly CD24lowCX3CR1hi in the steady state (lower, left).
After Flt3L, 70% of Langerin–CD11b  migDCs became
CD24hi CX3CR1low, suggesting that Flt3L expands this population selectively (lower, right). Collectively, these data suggest
that in the steady state Langerin–CD11b  cells are heterogeneous but Flt3L selectively expands a CD24hi CX3CR1low
subset, distinct from CD11b þ CD24low CX3CR1hi migDCs.

Langerin–CD11b  migDCs perform key DC functions

To further examine whether the Langerin–CD11b  subset
could perform key DC functions, we sorted CD8a LN-resident
cDCs and several migDC subsets from Langerin GFP mice
treated with Flt3L. We tested individual DC subsets (C57BL/6)
in the mixed leukocyte reaction (MLR) using T cells from
BALB/c mice. All DC types could effectively stimulate allogeneic T cells, including Langerin–CD11b  migDCs
(Figure 5a and b). In addition, we sorted and cultured DC
subsets with titrated doses of OVA protein and CD8 þ OT-1
transgenic T cells. Again, Langerin–CD11b  DCs were
comparable to other LN-resident and migDC subsets at OVA
antigen presentation to CD8 T cells ex vivo (Figure 5c and d,
gating, and representative flow data Supplementary Figure S4
online). These data suggest that Langerin–CD11b  migDCs

Langerin–CD11b  migDCs, similar to other cDCs, depend on
the transcription factor Zbtb46

To further characterize Langerin–CD11b  cells, we took
advantage of recently generated Zbtb46-diptheria toxin
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Figure 5. CD11b  migratory dendritic cells (migDCs) present antigen. CD11b  migDCs present allo-antigens in the mixed leukocyte reaction (a-b) and present
OVA protein (c-d) to CD8 þ Va2 OT-1 T cells with equal efficiency to other DC subsets ex vivo. One of two duplicate experiments is shown with triplicate wells
per sample.

perform equivalent antigen presentation of OVA to CD8 þ
T cells when compared with other DCs, including CD8a and
CD103 þ Langerin þ DCs.
Langerin–CD11b  migDCs relate closely to other skin DCs and
other cDCs, and express core DC signature genes

To further address the relationship of individual migDC
populations to each other and to cDCs in LNs, we performed
transcriptome analysis. We also included two additional
subsets of LN DCs in our analysis obtained from LPS-treated
mice: DC-SIGN þ monocyte-derived DCs and CD205 þ DCs
(Cheong et al., 2010) and peritoneal macrophages. Using
principal component analysis (PCA), we identified four distinct
clusters (data not shown): one cluster was formed by migDC
subsets including Langerin CD103 þ DCs, Langerin–
CD11b þ DCs, and Langerin–CD11b  DCs, consistent with
prior work suggesting that tissue DCs cluster together (Miller
et al., 2012). Hierarchy analysis (dendrogram) (Figure 6a)
revealed close relatedness of cutaneous Langerin–CD11b þ
and Langerin–CD11b  subsets to each other, and to
Langerin þ CD103 þ and CD8a cDCs when compared against
macrophages and LPS-treated DC subsets.

Recent studies have defined a ‘‘core-DC gene signature’’
when comparing multiple cDCs with macrophages (Miller
et al., 2012). By heat-map analysis, we analyzed the expression of many of these previously defined core DC genes in our
subsets, shown as a relative fold expression against
macrophages (Figure 6b). Many core DC genes including
Flt3, Ccr7, and Zbtb46 were upregulated in all DC subsets
examined, including Langerin–CD11b  migDCs. Heat-map
comparison of additional selected DC genes was also performed across all populations (Figure 6c). These include Irf8,
Clec9A, Ly75 (CD205, Dec205), Stat3, Zbtb46, Flt3, and
Ccr7. Irf8, a transcription factor necessary for CD8a (and its
equivalents) lineage development (Seillet et al., 2013), was
observed at the highest expression intensity in CD8a þ and
Langerin þ CD103 þ and in CD205 þ DCs despite LPS
treatment. CD11b  migDC levels of Irf8 were intermediate
but higher than in CD11b þ DCs, DC-Sign þ LPS-treated
monocyte-derived DCs, and macrophages.
DISCUSSION
This study characterizes a previously identified skin-resident
subset of immune cells (Henri et al., 2010) that we now
www.jidonline.org 1271
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demonstrate as migDCs sharing many properties to cDCs,
including Flt3L and Zbtb46 dependence. The current study
builds on prior work in which Langerin–CD11b  DCs along
with several other subsets were isolated from skin and skindraining LNs of mice. Previously, Langerin–CD11b  DCs were
noted to share division and repopulation kinetics along with
other dermal DCs such as Langerin þ CD103 þ DCs, suggesting
a common precursor (Henri et al., 2010), yet they have been
largely overlooked given the cross-presenting properties of
Langerin þ CD103 þ DCs. Here we provide a dedicated
characterization of Langerin–CD11b  migDCs based on developmental, phenotypic, and functional DC criteria, establishing
these cells as a distinct DC subset by transcriptome analysis and
relating them to other Flt3L-dependent classical DC subsets,
distinct from monocytes and macrophages.
We establish that Langerin–CD11b  DCs are heterogeneous in the steady state but contain a highly Flt3L-dependent
and -responsive population. Markedly reduced dermal
Langerin– CD11b þ and Langerin–CD11b  DC subsets
1272 Journal of Investigative Dermatology (2014), Volume 134

were gated from LNs in Flt3L  /  mice. Flt3L treatment preferentially expanded Langerin–CD11b  and
Langerin–CD11b þ dermal DC subsets in the LNs and in
the skin by crawlout explant. This may parallel spleen and
BM where Flt3L-expanded DCs consistently divide into
CD11bhi DC subsets (CD8a  cDC equivalents) and
CD11blow CD24hi SIRPalow-intermediate (CD8a þ cDC equivalents) (Naik et al., 2005). Langerin–CD11b  Flt3L-responsive
DCs, similar to classical CD8a þ CD11b  cDCs, are
CD24 þ and CX3CR1low and are efficiently depleted in DTtreated Zbtb46 DTR mice. Similar to other migDCs, we
determine that Langerin–CD11b  are CCR7 dependent,
are skin residents by explant and FITC painting, expand
locally in the skin in response to Flt3L, and may be visualized
in the dermis. Langerhans cells are radio-resistant, do not
express Flt3 (Ginhoux et al., 2012), and were not anticipated
to expand. These data suggest that Langerin– DCs comprise
the majority of the 14-fold Flt3L-based CD11c þ expansion
previously noted in the dermis (Esche et al., 1999).
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Although our study was conducted in mice, Flt3L dependence and Flt3L expansion of local cutaneous DC subsets is of
particular importance to the cancer vaccine arena, as current
and prior translational efforts aim to deliver cancer antigens to
DC after subcutaneous administration of Flt3L.
We observed that Langerin–CD11b  DCs from mice
treated with Flt3L performed allo-MLR and cross-presentation
to OVA at equal efficiency to LN-resident cDCs. This
suggests an efficient role in antigen presentation and bona fide
DC function. This may be of significance to priming
against erosive candida and cytolytic viruses where
residual T-cell priming by DCs occurs even in the absence of
Langerin þ CD103 þ dermal DCs, yet no other DC
subset in skin has been identified as responsible for residual
priming. However, strictly ex vivo analysis of DC function is
somewhat limited by the fact that migDCs mature in
culture after leaving the skin, and distinct individual in vivo
roles of cutaneous DC subsets are still incompletely
characterized. Current models of acute DC depletion
(Langerin–DTR, CD11B  DTR, Zbtb46-DTR, and CD11c 
DTR) cannot selectively isolate Langerin–CD11b  migDCs at
this time; therefore, it will be difficult to immediately resolve
their in vivo role in mediating cutaneous immunity. It is
possible that, when licensed to prime, DC subset activity in
the skin could relate to specialization or nonredundant coverage of various pathogens. Differing susceptibility of DC subsets
to infection may permit discrete roles in antigen presentation,
as observed for tissue-resident CD103 þ DCs versus alveolar
macrophages during influenza infection (Helft et al., 2012).
We have determined that migDC group together by hierarchy clustering. These data suggest that three dermal DC
subsets are closely related at the transcriptome level to each
other and may suggest that tissue microenvironment affects
terminal DC differentiation. As such, Langerin þ CD103 þ
DCs group more closely with other migDCs than with their
lymphoid developmental and functional equivalents: CD8a
cDCs. Perhaps in the steady state, tissue-resident migDCs may
act in concert. Intriguingly, LN CD205 þ cDCs from LPStreated mice cluster with LPS-treated DCs such as DC-SIGN þ
monocyte-derived DCs than to cDCs. The dominant gene
signatures relating these subsets in this context are likely
related to LPS treatment.
A lack of clarity surrounding the function and development of diverse DC subsets present in the skin and skin
draining LN has long hindered the development of vaccines
and clinical therapeutics to skin cancer. This work suggests
that the previously overlooked Langerin–CD11b  DC subset
contains a distinct, previously uncharacterized Flt3L-responsive migratory population with many properties of cDCs. As
such, Langerin–CD11b  DCs may serve as a potential target
of therapeutics aimed to enhance cutaneous immunity and as
a mediator of the cutaneous immune response.
MATERIALS AND METHODS

PBS versus sterile PBS-treated or untreated C57Bl/6 controls by IP
injection. ‘‘Tumor-treated’’ 8–12-week C57BL/6F or Langerin–GFP
mice were administered 5  106 murine Flt3L-secreting B16 melanoma tumor cells by subcutaneous injection. Doxycycline-inducible
models of Flt3L induction have been previously characterized
(Manfra et al., 2003). At 10–14 days of IP injection of Flt3L,
B10 mm tumor size, or after 8–12 days of doxycycline addition to
drinking water, mice were killed. Skin-draining LNs (inguinal,
brachial, axillary, popliteal, and superficial cervical pooled) and
spleen were isolated from individual mice. LNs and spleen were
added to Collagenase D (400 U ml  1, Roche) in Hanks’ Balanced Salt
Buffer (Gibco) solution. LNs were teased apart and spleens were
injected with this solution using a 22- to 23-gauge needle attached to
a 3-ml syringe, and incubated for 25 minutes at 37 1C (Steinman et al.,
1979). After incubation, 0.5 M EDTA was added to a final concentration of 10 mM EDTA for disruption of DC:T-cell complexes, and the
sample was further incubated for 5 minutes at 37 1C. For spleen cell
preparation, ACK lysis of red cells was performed. Undigested fibrous
material was filtered through a 70-mm cell strainer. Subsequent
washed were performed with ice-cold PBS with 2% fetal calf serum
(FCS). For crawlout assay, individual ears were harvested, washed in
70% EtOH, and both sides of ear halves were split dermal side down
into R5-RPMI medium with 10% FCS. Crawlouts were harvested in 6well plates (one ear per well), leading to some variability in total cell
counts across explants. At 72 hours, cell suspensions were isolated
and filtered. The pellet was washed twice and incubated in Fc block
with 2% rat serum before cell surface marker antibody staining.

Mice
C57BL/6 mice (B6) were purchased from Taconic Labs or bred at
Rockefeller University. CCR7  /  mice were bred at Rockefeller
University after being purchased from Jackson Laboratory (Bar
Harbor, ME) and are described with respect to defects in the skinderived DC migration (Martin-Fontecha et al., 2003; Martin-Fontecha
et al., 2008). Langerin–GFP mice were generously provided by
Bernard Malissen, bred as homozygotes at Rockefeller University,
and have been previously described (Kissenpfennig et al., 2005).
CX3CR1-GFP mice were purchased from Jackson Laboratory and
previously described (Jung et al., 2000). Zbtb46-DTR mice were
generously provided by Matthew Meredith and Michel Nussenzweig.
Doxycycline-inducible Flt3L were kindly provided by Sergio Lira. All
mice were housed in specific pathogen-free conditions. Protocols
were approved by the Rockefeller University and Harvard University
Animal Care and Use Committees.

DC isolation
For allo-MLR, OVA presentation, and microarray RNA isolation, DC
subsets were sorted from 5–10 pooled Flt3L-treated Langerin–GFP
mice per experiment. Following size, live/dead, and exclusion criteria
(CD3, CD19, NK1.1 exclusion) DC subsets were sorted following the
general gating schema depicted in S1a. DC-SIGN þ and CD205 þ
DCs were sorted from the skin-draining LNs of C57BL/6 mice
24 hours after intravenous injection of 5 mg of LPS (Cheong et al.,
2010), and macrophages were isolated from the peritoneum.

Tissue harvest and DC cell preparation
‘‘Flt3L-treated’’ mice were injected by the intraperitoneal (IP) route
with endotoxin-free (o0.0064 EU mg  1), GMP-grade, recombinant
human Flt3L (Celldex) at 10 mg per mouse per day, diluted in sterile

Immunofluorescence
Back skin from Flt3L-treated (12 days) or -untreated C57BL/6 controls
was isolated and frozen in tissue-tek OCT (Sakura Finetek, Torrance,
www.jidonline.org 1273
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CA). Sections (6 mm) were cut by cryomicrotome (Leica, Norcross,
GA) sectioning, air-dried, and fixed in ice-cold acetone. Sections
were pretreated with endogenous avidin/biotin block (Invitrogen,
Carlsbad, CA) and further blocked with 10% normal goat serum
(Jackson ImmunoResearch Laboratories). Sequential immunofluorescence staining was performed using anti-langerin (clone 929F3,
Dendritics, Lyon, France), anti-CD11b (clone M1/70; Biolegend,
San Diego, CA), and anti-CD11c (clone HL3, BD Biosciences,
San Jose, CA) with the appropriate secondary antibodies (anti-rat
IgG2a FITC (eBioscience, San Diego, CA), anti-rat IgG2b eFluor570
(eBioscience), and streptavidin-Alexa Fluor 647 (Invitrogen). Sections
were mounted with Vectashield with DAPI (Vector Labs, Burlingame,
CA). Images were acquired on a VS120 Whole Slide Scanner
(Olympus, Center Valley, PA) at  10 magnification using the ASW
software and analyzed using the Olyvia software (Olympus).

Microarray analysis, normalization, and data analysis
RNA samples were prepared by standard methods using Trizol
(Invitrogen) and further purified using RNeasy MinElute cleanup
(QIAGEN, Valencia, CA). Purity analysis was performed by nanodrop
and Eukaryote Total RNA Pico Series II (Agilent). RNA was amplified
and hybridized on the Illumina MouseRef-8 v2.0 Expression BeadChip. For subset analysis, at least three replicates were analyzed from
individual sorts to achieve statistical significance. Raw data from
Illumina single-color chips were analyzed with GeneSpring 12.5
(Agilent Technologies, Santa Clara, CA). Intensities below background were replaced with the average background over all samples.
Quantile normalization was applied to have a common distribution of
intensities, followed by log2 transformation. Normalized values were
baseline-transformed to the median of all samples. Normalized data
were filtered to eliminate probes with low expression with a
coefficient of variation of 40.5 in population samples. One-way
ANOVA was used to find statistically significant differences among
probes (P-values corrected with Benjamini–Hochberg false discovery
method set at Po0.05). All DC subsets were arranged by a
hierarchical clustering algorithm using normalized intensity values
and based on twofold change or greater of all genes (n ¼ 8601). Heat
maps for the differential expressions of core DCs relative to macrophages (two-fold) were generated and analyzed (Figure 6c). For
selected DC genes of interest, heat maps of normalized intensity
values were generated (Figure 6d). All data sets have been deposited
at the National Center for Biotechnology Information/GSE53588.

anti-Ly6c (HK1.4), anti-B220 (RA3-6B2), anti-I-A/I-E (M5/114.15.2),
anti-CD3 (17A2), anti-CD19 (eBio1D3), and anti-NK1.1 (PK136).
AQUA (L34957) was from Invitrogen. Cytofix/cytoperm kit was from
BD Biosciences. CFSE was from Sigma. Anti-CD205 (NLDC-145) was
produced in the Steinman lab and conjugated to Alexafluor 488 or 647.
Other reagents included PBS and FBS (Gibco-BRL), and ACK lysing
buffer (BioSource, Invitrogen, Carlsbad, CA). Staining with anti-Langerin
and anti-CD205 was performed with cell surface and intracellular label
as described (Cheong et al., 2007). For intracellular blocking, 2% rat
serum was diluted into perm/wash buffer. All extracellular staining was
performed in ice-cold PBS with 2% FCS. FITC painting was performed
on the flank with 1:1 1% FITC in acetone:Dibutyl phthalate (.5%
FITC final) for 16–30 hours before harvest.

OVA presentation
Endotoxin-free (o0.001 EU mg  1) OVA was purchased from Hyglos
(Bernried, Germany). For all groups, equal total numbers of DC
subsets and CFSE-labeled T cells were cultured at a 1:10 ratio with
increasing concentrations of soluble OVA protein.

MLR
Allo-MLR was performed as previously described (Anandasabapathy
et al., 2011) from FACS-sorted LN-resident and migDC subsets
isolated from the skin-draining LNs.
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Flow cytometry and gating
Cells were stained on ice in PBS with 2.0% (vol/vol) FCS. LSR II
(Becton Dickinson, Franklin Lakes, NJ) was used for multiparametric
flow cytometry of stained cell suspensions, followed by analysis with
the FlowJo software (TreeStar).

Antibodies, live/dead dye, CFSE, FITC painting, and staining
reagents
The following reagents were from BD Biosciences, eBioscience, or
Biolegend: anti-Langerin (eBioL31), anti-CD11c (N418), anti-CD4
(RM4-5), anti-CD8a (53-6.7), anti-CD11b (M1/70), anti-CD103 (2E7),
anti-Armenian Hamster IgG Isotype Control (eBio299Arm), anti-rat
IgG2a Isotype Control (eBR2a), anti-CD3 (500A2), anti-CD45
(30-F11), anti-CD205 (NLDC-145), anti-EPCAM (G8.8), anti-CD24
(M1/69), anti-F4/80 (BM8), anti-CD115 (AFS98), anti-PDCA1 (ebio927),
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